Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPINE 1: Phase 2b dose-finding study of BAY 3283142 in chronic kidney disease
jRCT2031240249Phase 2Active, not recruiting
- Sponsor
- Bayer
- Start
- Aug 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of BAY3283142 in chronic kidney disease (CKD) (6 arms), sponsored by Bayer. Primary endpoint: Change from baseline to Week 16 in log-transformed UACR. Started Aug 2024; status: active, not recruiting.
02
Drugs
BAY3283142
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2031240249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240249.